NHS Framework Agreement for the Supply of Human Normal Immunoglobulin & Anti-D Immunoglobulin
The value below is a framework or dynamic market ceiling: the maximum
that could be spent across all call-offs, not the value of a single contract.
Aggregate figures on this site exclude these to avoid double counting.
key details
| Value | £526,598,540 |
|---|---|
| Status | planned |
| Category (CPV) | 33651520 |
| Region | Scotland, Northern Ireland |
| Contract start | 1 Jul 2025 |
| Contract end | 31 Dec 2026 |
| Procedure | open |
| SME suitable | Yes |
| OCID | ocds-b5fd17-dab4487b-26eb-4085-a167-4a0c43642071 |
description
Human Normal Immunoglobulin & Anti-D Immunoglobulin
The purpose of this 'future opportunity' notice is to indicate that a live 'opportunity' may be published at a future date. However, any existing 'live' framework agreement may be subject to an extension up to the maximum extension period allowedHuman Normal Immunoglobulin & Anti-D Immunoglobulin
notice history
2 notices published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 3 Feb 2023 | Planning (planning) | · | 986e5e89-4eb5-45dc-8098-ed5508ac0991-611773 |
| 3 Feb 2023 | Planning (planning) | · | ba54be46-877e-4f98-a557-6079ad634ec3-611775 |
more from NHS ENGLAND
- Products for the treatment of Haemophilia A · £215,000,000 · 11 May 2023
- NHS Framework Agreement for the supply of products for the treatment of Haemophilia A · £215,000,000 · 26 Apr 2023
- NHS Framework Agreement for the supply of Adult Influenza Vaccines - Secondary Care · £16,000,000 · 22 Jul 2022
- National Framework Agreement for the supply of products for the management of Hereditary Angioedema · £74,500,000 · 5 Jul 2022
- NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema · £74,500,000 · 5 Jul 2022
- NHA National Framework Agreement for the supply of products for the treatment of Bleeding Disorders including Haemophilia B · £250,000,000 · 5 Jul 2022
- NHS National Framework Agreement for the supply of products for the treatment of Haemophilia A · £214,000,000 · 22 Mar 2022
- NHS National Framework Agreement for the supply of products for the management of Herediatary Angioedema · £74,500,000 · 3 Feb 2022
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin · NHS England · £1,200,000,000
- NHS Framework Agreement for the supply of Human Immunoglobulin and Anti-D Immunoglobulin · NHS ENGLAND
- SUPPLY OF BOTULISM ANTITOXIN HEPTEVALENT (HBAT) · Ministry of Defence
- SARS-CoV-2 Nucleocapsid proteins for LFT Revalidation and Testing · UK Health Security Agency · £500,000
- CMU Framework for the supply of Anti-D Immunoglobulin · University Hospitals of Leicester NHS Trust · £209,801
- PHE_Scientific Provision for purchase of the Euroimmun Anti SARS CoV 2 IgG assay · Public Health England · £158,400
- NHS Framework Agreement for the Supply of Human Normal Immunoglobulin (Panzyga) · The NHS Commissioning Board (operating under the name of NHS England)
- 1LHE Goods - Antibodies · NEWCASTLE UNIVERSITY · £25,115
source
Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.